how the standard of care for dlbcl is changing with the introduction of novel agents
Published 1 year ago • 121 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
1:02
the changing standard of care in dlbcl
-
14:25
an overview of novel innovative treatments for patients with von willebrand disease
-
2:03
novel treatment approaches for early-stage dlbcl
-
3:39
the role of novel therapies in r/r dlbcl
-
1:05
updates on tafasitamab for the treatment of dlbcl
-
1:45
improving the frontline treatment of dlbcl
-
29:38
dlbcl treatment approaches: what you need to know
-
10:09
understanding diffuse large b-cell lymphoma with jennifer amengual, md
-
5:31
sd lipidocare user manual
-
4:29
treatment strategies in older patients with aml
-
1:31
the current state of treatment for limited-stage dlbcl
-
4:01
first- and second-line treatment in dlbcl
-
6:33
new data on dlbcl in the uk and its impact on treatment decisions
-
7:16
changes in the classification of dlbcl
-
1:20
improving patient outcomes in ctcl: clinical collaboration and novel agents
-
1:19
contemporary approaches to the management of r/r dlbcl
-
1:15
personalized medicine for dlbcl
-
0:51
the promise of cd30-targeting cellular therapies in hl
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
3:04
applying molecular understanding of dlbcl to management strategies